血液HER2与尿调节素是CKD的因果介导因素
研究采用孟德尔随机化方法,在ORIGIN试验4147例早期或前期糖尿病患者中筛选227种血清蛋白标志物的遗传决定因素,并在CKD遗传学联盟(n=117165,12385例病例)中评估其对CKD的效应。结果发现尿调节素(UMOD)和人类表皮生长因子受体2(HER2)是CKD的新型因果介导因素,血清HER2水平部分受ACE调控,二者为CKD预防的潜在治疗靶点。
要点
- UMOD与HER2均为CKD的独立因果介导因素,每SD的OR均为1.30。
- ORIGIN参与者中血HER2浓度与CKD事件相关(OR 1.07/SD)。
- ACE是HER2水平的调节因素,ACE抑制剂使用与HER2水平呈反向关系。
核心结论
- UMOD和HER2是人CKD的独立因果介导因素,血清HER2水平部分由ACE调控,这些标志物是CKD预防的潜在治疗靶点。
研究设计与样本
- 孟德尔随机化研究:先于ORIGIN试验4147例早期或前期糖尿病参与者中鉴定227种血清蛋白标志物的遗传决定因素。
- 在CKD遗传学联盟(n=117165;12385例病例)中用逆方差加权(固定效应)法评估标志物对CKD的效应。
- 随后在ORIGIN参与者中估计所鉴定标志物血清浓度与 incident CKD 的关系。
主要发现
- UMOD:每SD OR 1.30(95%CI 1.25至1.35;P<5×10-20)。
- HER2:每SD OR 1.30(95%CI 1.14至1.48;P=8.0×10-5)。
- ORIGIN参与者中血HER2浓度与CKD事件相关:每SD OR 1.07(95%CI 1.01至1.13;P=0.01)。
- 探索性MR分析显示ACE调节HER2水平(β=0.13/SD;95%CI 0.08至0.16;P=2.5×10-7),ACE抑制剂使用与HER2水平呈反向关系。
临床怎么用
- 可将UMOD与HER2作为CKD因果标志物认识,并作为潜在预防干预靶点;ACE抑制剂与HER2水平的关系值得临床关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many biomarkers have been epidemiologically linked with CKD; however, the possibility that such associations are due to reverse causation or confounding limits the utility of these biomarkers. To overcome this limitation, we used a Mendelian randomization (MR) approach to identify causal mediators of CKD. We performed MR by first identifying genetic determinants of 227 serum protein biomarkers assayed in 4147 participants of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial who had early or prediabetes, and assessing the effects of these biomarkers on CKD in the CKD genetics consortium (n=117,165; 12,385 cases) using the inverse-variance weighted (fixed-effects) method. We then estimated the relationship between the serum concentration of each biomarker identified and incident CKD in ORIGIN participants. MR identified uromodulin (UMOD) and human EGF receptor 2 (HER2) as novel, causal mediators of CKD (UMOD: odds ratio [OR], 1.30 per SD; 95% confidence interval [95% CI], 1.25 to 1.35; P<5×10-20; HER2: OR, 1.30 per SD; 95% CI, 1.14 to 1.48; P=8.0×10-5). Consistent with these findings, blood HER2 concentration associated with CKD events in ORIGIN participants (OR, 1.07 per SD; 95% CI, 1.01 to 1.13; P=0.01). Additional exploratory MR analyses identified angiotensin-converting enzyme (ACE) as a regulator of HER2 levels (β=0.13 per SD; 95% CI, 0.08 to 0.16; P=2.5×10-7). This finding was corroborated by an inverse relationship between ACE inhibitor use and HER2 levels. Thus, UMOD and HER2 are independent causal mediators of CKD in humans, and serum HER2 levels are regulated in part by ACE. These biomarkers are potential therapeutic targets for CKD prevention.
引用
- Sjaarda J, Gerstein HC, Yusuf S, et al. Blood HER2 and Uromodulin as Causal Mediators of CKD. J Am Soc Nephrol. 2018. PMID: 29511113. doi:10.1681/ASN.2017070812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。